Complete Health Care Guide

The Committee for Medicinal Products for (HUEMA), has decided to authorize the use of Spanish antitumor Yondelis for tumors of recurrent ovarian cancer. Yondelis is the trading name of trabectedin, ET-743 or as named in the laboratory. It is a synthetic derivative of a marine compound, the ‘Ecteinascidia turbinata’, already used in European countries today to treat other cancer.

It can be used via the compassionate use (where no alternative therapy) to treat ovarian tumors that relapsed despite receiving other standard therapy after platinum-based. Oncologists may be administered to patients who have no other therapeutic indication, but not formally adopted in either case. However, the official decision of the Agency on its use for women with ovarian cancer and platinum-sensitive relapse.

Possibility Related Posts:

• Patient Survival
  Expectations  Of Ovarian cancer is rarely diagnosed in its early stages and is generally well advanced at the time of diagnosis, which often provides a poor prognosis. Approximately 76% of women w...